Cholesterol levels are something that many people tend to struggle with, but with the right information and lifestyle changes ...

Already approved for smoking and treatment-resistant depression, brain stimulation is being tested for multiple addictions ...

SPRINGFIELD, Ill. – The Illinois Department of Public Health (IDPH) has approved four new conditions for treatment with ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

For stronger daytime dry eye relief when regular drops just aren’t cutting it, this everyday soothing eye gel by Refresh ...

Bernstein analyst William Pickering maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $63.00.

An extended course of Paxlovid appears to help some patients with long Covid, according to research that suggests this treatment option holds promise for some of those struggling with debilitating ...

NYPRG-101 is under clinical development by Ceruvia Lifesciences and currently in Phase I for Alcohol Dependence.

LuAG-06474 is under clinical development by H. Lundbeck and currently in Phase I for Unspecified Neurologic Disorders.